Phase III FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer
Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine the safety and efficacy of a chemotherapy regimen
known as Modified FOLFIRINOX (mFFX) alone or with the addition of Stereotactic Body
Radiotherapy (SBRT). We hope to learn if this new treatment combination helps to control the
disease and improve survival for patients with locally advanced pancreatic cancer.